Core Viewpoint - Senseonics Holdings, Inc. has launched an integration of its Eversense 365 continuous glucose monitoring (CGM) system with Sequel MedTech's twiist AID system, marking a significant advancement in diabetes management technology [1][2][4]. Group 1: Product Integration and Features - The integration of the twiist AID system with Eversense 365 provides type 1 diabetes patients with enhanced flexibility and personalization in managing their condition [2][4]. - Eversense 365 is the only implantable CGM available, offering one year of accurate monitoring with minimal interruptions, which helps patients focus on diabetes management rather than on the CGM itself [3][5]. - The twiist AID system utilizes iiSure™ technology for rapid insulin delivery measurement and occlusion detection, enhancing accuracy and efficiency compared to other AID systems [3]. Group 2: Company Goals and Market Position - Senseonics aims to improve the lives of diabetes patients by simplifying and personalizing diabetes management through the integration of its CGM with the twiist AID system [4]. - Sequel MedTech emphasizes the importance of personalization in diabetes management, aiming to provide choices for patients and enhance their confidence in managing their condition [4]. - Broad availability of the integrated twiist and Eversense 365 products is anticipated by March 2026, indicating a strategic move to capture a larger market share in diabetes management solutions [4]. Group 3: Technical Specifications - Eversense CGM systems are indicated for continuous glucose level measurement for up to 365 days for Eversense 365 and 180 days for Eversense E3, replacing traditional fingerstick blood glucose measurements [6]. - The systems require periodic fingerstick calibrations, with specific guidelines for frequency based on the duration of use [6][8]. Group 4: Company Background - Senseonics is focused on developing and commercializing long-term implantable glucose management technologies, aiming to transform the lives of individuals in the diabetes community [8]. - The Eversense CGM systems consist of a small sensor inserted under the skin, which communicates glucose data to a smart transmitter worn externally, providing real-time monitoring [8].